Pharvaris NV

Pharvaris insider sales show routine 10b5‑1 divestitures, no sharp price impact—focus remains on strong quarterly results and future clinical milestones.

Pharvaris insider trades reveal executives buying at €2.59 and selling around €30, showing confidence in the company’s rare‑disease pipeline and future milestones.

Pharvaris NV insider selling: CEO’s modest 23,333‑share sale amid a 10% rally signals routine portfolio management, not a bearish warning. Learn how this move reflects executive confidence and impacts investor strategy.

Pharvaris insider selling signals a strategic re‑balance, offering investors early insight into the company’s pipeline confidence and portfolio strategy.

Pharvaris insider sale: Nijdam Anna sells 1,164 shares amid upcoming Phase 3 results—signals routine portfolio balance, not a bearish warning.

Pharvaris NV insider Abele Stefan Andreas adjusts holdings, boosting investor confidence amid active social‑media buzz and strong Phase 3 clinical progress.

Pharvaris insider Souverijns keeps 55k shares, showing strong confidence in its B2 antagonist pipeline and a long‑term growth outlook.